Latest Conference Articles

The motive of the study wasn't to implement hematopoietic stem cell transplantation (HSCT) programs worldwide, but as a contribution to comprehensive cancer control efforts.

According to Dr. Corinna Schultz, a key part of the conversation of sickle cell trait (SCT) is centered around reproductive choices for the patient in the future.

Dr. Adam Lamble recommends that pediatric patients with AML and TP53 status should now be considered for transplant in first remission, and novel interventions are warranted.

Dr. Molly Tokaz and Dr. Lisa Force discuss the extensive data they collected on the utilization of hematopoietic stem cell transplantation (HSCT) for patients with AML.

Almost 25 years later, Dr. Claudia Morris concluded 2022 by presenting phase 2 data at the 64th ASH Annual Meeting that demonstrated the therapy's benefit, and her original premise. Her team's phase 3 trial evaluating Arg is currently underway.

Dr. Adam Lamble shares that outcomes for pediatric patients with acute myeloid leukemia that have TP53 status are inferior to other patients with high-risk disease.

Dr. Corinna Schultz talks about her latest data and the growing body of literature showing medical complications that can come with sickle cell trait.

New developments in gene therapy offer a promising perspective of a future where curing sickle cell disease (SCD) is possible.

Expert Stephanie Guarino, MD, MSHP, shares her plan for the future of pain management specifically for sickle cell disease is based on results from a series of studies.

The most common thrombophilia types were heterozygosity for factor V Leiden, prothrombin 20210A mutation, and protein S deficiency.

More research presented by Dr. Stephanie Guarino resulted in a recommended guideline designed for investigating sickle cell disease pain to standardize and enhance the quality of data.

In a late-breaking abstract presented during ASH 2022, investigators found patients treated with PTCy had a significantly lower hazard of GRFS than the standard therapy group.

A recent study presented at ASH 2022 examined the safety profiles of different hormonal contraceptives for female sickle cell disease patients at risk of thromboembolism.

The advisory committee voted 3-8 against the benefit-risk profile of omecamtiv mecarbil for heart failure with reduced ejection fraction.

The treatment was superior in various secondary endpoints, included transfusion avoidance, changes from baseline in hemoglobin level, FACIT-F scores and ARC, and the rate of clinical BTH.

Data from the largest investigation of TP53 mutations in pediatric patients with acute myeloid leukemia (AML) is presented at the ASH 2022 Annual Meeting.

"There's no national guidance on how this information should be delivered back to families, which leaves it up to each state's newborn screening program to decide the best route that they see fit," Dr. Corinna Schultz explains.

New phase 2 interim data show rates of the erectile condition were halved after 26 weeks of treatment.

Dr. Stephanie Guarino's novel analysis found a significant relationship between self-efficacy in adults with SCD, and experiences of disease-related stigma.

New research presented at ASH 2022 and conducted following a Hemophilia-Related Distress Questionnaire indicated racial disparities between White and Black patients.

Spleen size can vary significantly in pediatric patients with sickle cell anemia.

In her mitochondrial work, Dr. Claudia Morris made a novel discovery that wasn't discussed in her presentation at the ASH 2022 Annual Meeting.

The results show the mean change from baseline in PKDD was ‒7.19 for M/M patients, ‒4.58 for P/M patients, and ‒3.94 for mitapivat patients.

"Acute myeloid leukemia (AML) remains the most deadly disease among adults, with a five year overall survival of less than 30%," lead investigator Dr. Molly Tokaz says in an interview.

The results for emotional functioning, social functioning, and nausea and vomiting numerically favored D-Rd at several time points.

New research presented at ASH 2022 showed survival rate improvements for APL patients through a simplified treatment algorithm designed by the trial investigators.

The accurate prediction of EF trajectory phenotypes may determine personalization of prognosis and treatment in a pediatric population with acute myeloid leukemia.

New research assessed whether the T117S gene variant could be useful as a marker for predicting sickle cell disease patients' might responses to hydroxyurea treatment.

Researchers from Germany suggest the utility of platelet and absolute neutrophil counts may be misplaced in current standards for pediatric remission.

Every patient in the study was VOC-free at the time of the data cut.